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Summary
 
Neutrophil-specific granule deficiency (SGD) is a rare disorder characterized by recurrent pyo-
genic infections, defective neutrophil chemotaxis and bactericidal activity, and lack of neutro-
phil secondary granule proteins. CCAAT/enhancer binding protein (C/EBP)
 
e
 
, a member of
the leucine zipper family of transcription factors, is expressed primarily in myeloid cells, and its
knockout mouse model possesses distinctive defects, including a lack of neutrophil secondary
granule proteins. Sequence analysis of the genomic DNA of a patient with SGD revealed a
five-basepair deletion in the second exon of the C/EBP
 
e
 
 locus. The predicted frame shift re-
sults in a truncation of the 32-kD major C/EBP
 
e
 
 isoform, with loss of the dimerization do-
main, DNA binding region, and transcriptional activity. The multiple functional defects ob-
served in these early neutrophil progenitor cells, a consequence of C/EBP
 
e
 
 deficiency, define
SGD as a defect in myelopoiesis and establish the requirement for C/EBP
 
e
 
 for the promyelo-
cyte–myelocyte transition in myeloid differentiation.
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eutrophil-specific granule deficiency (SGD) is a rare
congenital disorder marked by frequent and severe
bacterial infections. The five reported cases consistently
describe pleiotropic characteristics, including lack of sec-
ondary granule proteins and defensins, abnormalities in
neutrophil migration and disaggregation, atypical nuclear
morphology, and impaired bactericidal activity (1–11).
More recent work has revealed additional granule abnor-
malities in the eosinophils of SGD patients, with absence of
eosinophil-specific granule contents, including eosinophil
cationic protein, eosinophil-derived neurotoxin, and major
basic protein (12). Platelet disorders and associated bleeding
diatheses, including the neutrophilic phagocytosis of plate-
lets (13) and the absence of platelet–high-molecular-mass
von Willebrand factor multimers stored in platelet 
 
a
 
 gran-
ules (14), have also been reported in SGD patients. In con-
trast to these seemingly genetically unrelated manifestations,
these patients express normal levels of salivary lactoferrin (8,
15, 16), a characteristic specific granule marker absent in
neutrophils in SGD, suggesting that the responsible defect
involves myeloid-specific transcriptional regulation.
CCAAT/enhancer binding proteins (C/EBPs) comprise
a family of transcription factors that are key regulators of
cellular differentiation and function in a variety of tissues
(17). The prototypic C/EBP is a modular protein consist-
ing of one or more activation domains, a dimerization basic
zipper domain and a DNA binding region (18). C/EBPs
are least conserved in their activation domains and vary
from dominant negative repressors to strong activators.
C/EBP
 
e
 
, the newest member of the family, is expressed
exclusively in cells of myeloid and T cell lineage (19–22).
The human C/EBP
 
e
 
 gene encodes four mRNA isoforms
with varying splice patterns, driven from two alternative
promoters, and from which are translated three protein iso-
forms (23). Analogous to what has been shown for C/EBP
 
a
 
and C/EBP
 
b
 
 (24, 25), in vitro transfection data suggest
that the full length, 32-kD isoform of C/EBP
 
e
 
 (C/EBP
 
e
 
32
 
)
possesses the fully active transcriptional activation domain,
whereas the short, 14.2-kD isoform (C/EBP
 
e
 
14
 
) lacks tran-
scriptional activity (23).
Nearly 60% of C/EBP
 
e
 
 knockout mice (26) succumb to
low pathogenicity bacterial infections by 4–6 mo of age.
Neutrophils from C/EBP
 
e
 
 knockout mice have morpho-
logical features similar to human SGD neutrophils, includ-
ing bilobed nuclei, absent specific and tertiary granule con-
tents, and defective chemotaxis and bactericidal activity
(27). The striking phenotypic similarities between SGD
defects and the C/EBP
 
e
 
 knockout model prompted a
search for a C/EBP
 
e
 
 knockout mutation in an SGD pa-
tient’s genomic locus. 
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Materials and Methods
 
Patient.
 
Material from a previously described (5, 6) male pa-
tient lacking neutrophil-specific granules was studied. Research
was conducted with informed consent under the guidelines of a
National Institutes of Health
 
 
 
(NIH) Internal Review Board–
approved protocol, no. 92-I-99. The patient died from complica-
tions of pneumonia at age 20.
 
DNA, RNA, and Protein Extraction.
 
Peripheral blood neutro-
phils were isolated as described (28), cryopreserved with dimeth-
ylformamide (Sigma Chemical Co.), and maintained at 
 
2
 
140
 
8
 
C.
Cell proteins were extracted as described (29). DNA extraction
from cryopreserved fibroblasts proceeded as described (30). RNA
was extracted from patient bone marrow aspirate using RNAzol
reagent (Teltest) as per manufacturer’s protocol. Normal human
bone marrow RNA was purchased from Clontech.
 
PCR Amplification of Genomic Sequence.
 
PCR reaction was
performed using Platinum taq DNA polymerase (Life Technolo-
gies) per manufacturer’s instructions and cycled as follows: 96
 
8
 
C
for 12 min, followed by a three-step cycle—94
 
8
 
C for 30 s, 60
 
8
 
C
for 30 s, and 72
 
8
 
C for 2 min—for 35–40 cycles. PCR products
were gel purified and recovered using Gene Clean (Bio101).
Products were sequenced with an ABI Prism Dye Terminator
Cycle Sequencing Ready Reaction Kit (Perkin-Elmer Corp.).
Primers were chosen from a published sequence available from
EMBL/GenBank/DDBJ under accession no. U48865. Primer
sets (upstream, downstream): B, 5
 
9
 
-AGC GGC CAT GCA AAA
GGA AAG ACA, 5
 
9
 
-TCC ACC TAC CCC CAA GAG AAA
GTT (bp 667–1186); C, 5
 
9
 
-CCC ACG GGA CCT ACT ACG
A, 5
 
9
 
-GGG CTG GCC TGC TCT TAC (bp 1818–2343); F, 5
 
9
 
-
CTC CCC GGC TGG CCC CTT ACA C, 5
 
9
 
-GCC AAC
AGT CCC AAC ACC CAG TCA (bp 3133–3615); G, 5
 
9
 
-GGA
GGT GGG GCT ACA AAA GAA ACT, 5
 
9
 
-TCA GGG AGG
GGC AGG ACA (bp 1143–1553); H, 5
 
9
 
-ACA GGA GTG GGT
GAC AGA GGA GAC, 5
 
9
 
-GGG CCG AAG GTA TGT GGA
GGG TAG (bp 1563–2104); I, 5
 
9
 
-CCA TGC CCC CTC CTC
TTG TTT CTC, 5
 
9
 
-ACT GCC TTC TTG CCC TTG TGT
AA (bp 2594–3171); K, 5
 
9
 
-AAC TTT CTC TTG GGG GTA
GGT GGA, 5
 
9
 
-TCG TAG TAG GTC CCG TGG (bp 1163–
1837). Homozygosity was determined by hybridization of the
PCR product fragment C to a [
 
32
 
P]
 
g
 
dATP-endlabeled internal
oligonucleotide (H. downstream; sequence above). Labeled oligo
was mixed with hybridization buffer (75 mM NaCl, 5 mM EDTA)
in a ratio of 1:10, and 10 
 
m
 
l was added to 30 
 
m
 
l PCR product.
Hybridization was cycled in a thermal cycler: 95
 
8
 
C for 5 min and
55
 
8
 
C for 10 min. Reactions were immediately placed on ice.
Products were resolved on 4–20% Tris/borate/EDTA polyacryl-
amide gel (Novex) at 250 V.
 
RNA Blotting Assay.
 
10 
 
m
 
g of total RNA isolated from the
patient’s bone marrow and 0.25, 0.5, and 1 
 
m
 
g of control poly-
adenylated (pA)-mRNA was electrophoretically separated, blot-
ted, hybridized, and washed as described (27). The membrane
was stripped by boiling and stored at 
 
2
 
20
 
8
 
C.
 
Immunoblotting.
 
Protein quantitation was performed using a
BCA Protein Assay kit (Pierce Chemical Co.) according to the
manufacturer’s instructions. 10–100 
 
m
 
g protein extracts were
Figure 1. (A) Sequence data from PCR
products of normal control genomic DNA
(top) and SGD patient DNA (bottom). Se-
quencing was performed on three separate
PCRs from the SGD patient and three nor-
mal controls. Color coding of nucleotides
on sequence scan is red, T; green, A; black,
G; blue, C. Underlined nucleotides, 5-bp
deletion. Arrowhead, location of deletion in
the SGD patient sequence. Schematic draw-
ing of C/EBPe locus shows three exons;
two alternative promoters, Pa and Pb;
translational start codons; and bZIP region.
(B) Schematic drawing of the three human
C/EBPe protein isoforms. Second drawing
(from top) shows the C/EBPe32-SGD iso-
form with predicted missense region and
premature termination codon occurring af-
ter the arrowhead. (C) PCR products after
liquid hybridization of DNA region con-
taining 5-bp deletion. Lanes 1 and 2, nor-
mal controls. Lane 4, patient DNA. Lane 3,
PCR products from normal control DNA
mixed equimolar with patient DNA. Ar-
rowheads indicate normal allele (top) and
SGD allele (bottom). Over 30 normal con-
trols were tested. 
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Dual-Light kit (Tropix, Inc.), according to the manufacturer’s
protocol, on a Turner 20/20 Luminometer. Samples were read
for 15 s after a 3-s delay.
 
Results and Discussion
 
Sequencing of PCR products from genomic DNA de-
tected a 5-bp deletion, TGACC, in exon 2 of the patient’s
C/EBP
 
e
 
 sequence. Fig. 1 A shows sequence data from one
normal control (top sequence) and the SGD patient (bot-
tom sequence). The mutation predicts a frameshift and a
premature termination of the encoded C/EBP
 
e
 
32
 
 isoform
(Fig. 1 B). The missense code after the frameshift results in
the loss of the critical DNA binding domain and leucine
zipper region required for C/EBP dimerization and func-
tion. C/EBP
 
e
 
 transcripts encoding the shorter 27- and 14-
kD isoforms are predicted to be unaffected, based upon the
splice donor and acceptor and translational start sites (23).
Homozygosity of the deletion was determined by PCR
amplification of the affected region and resolution of the
DNA fragments on a 4–20% polyacrylamide gel (Fig. 1 C).
DNA from one normal control and the SGD patient were
mixed before amplification and electrophoresis (lane 3),
showing bands from both affected and normal alleles. In
comparison, PCR products from the SGD patient (lane 4)
and normal controls (lanes 1 and 2) show only one frag-
ment, indicating homozygosity for their respective alleles.
RNA blot analysis of the SGD patient’s bone marrow
total RNA showed decreased amounts of C/EBP
 
e
 
 tran-
scripts in comparison with control human bone marrow
pA-RNA (Fig. 2 A). Hybridization with a [
 
32
 
P]dCTP-
labeled actin probe (provided by L. Perera, National Cancer
Institute, NIH) showed that 10 
 
m
 
g of SGD patient bone
marrow total RNA was equivalent to 1 
 
m
 
g of normal bone
marrow pA-mRNA and verified the stability and quality of
the patient’s RNA preparation. Specific loss of C/EBP
 
e
 
transcripts in the SGD patient is likely due to mRNA insta-
bility secondary to the frameshift and the premature termina-
tion codon, as seen in other similar gene mutations (32, 33).
Residual C/EBP
 
e
 
 message is likely comprised by C/EBP
 
e
 
14
 
and C/EBP
 
e
 
27
 
 transcripts, which are unaffected by the
5-bp deletion and similar in size to the C/EBP
 
e
 
32
 
 tran-
script. Transcripts of C/EBP
 
a
 
 were present in normal
amounts. C/EBP
 
a
 
 has a more proximal role in the my-
elopoietic pathway and specifically induces expression of
C/EBP
 
e
 
 (31, 34, 35). As expected, message for lactoferrin
was not detected in the SGD patient’s bone marrow RNA.
As predicted from the C/EBP
 
e
 
 transcript maps (Fig. 1
B), immunoblotting detected C/EBP
 
e
 
27
 
 and C/EBP
 
e
 
14
 
isoforms, but not C/EBP
 
e
 
32
 
, in neutrophils from the SGD
patient (Fig. 2 B). All three isoforms were seen in the nor-
mal control. The antibody used is specific for a peptide se-
quence immediately downstream of the 5-bp mutation and
should not bind the C/EBP
 
e
 
32
 
-SGD protein.
Transient transfection assays in HeLa cells, using the G-CSF
receptor promoter driving the luciferase gene (31), com-
pared the transactivation potentials of the inducer genes
C/EBP
 
a
 
, C/EBP
 
e
 
32
 
, C/EBP
 
e
 
14
 
, and C/EBP
 
e
 
32
 
-SGD
Figure 2. (A) RNA blot of SGD patient bone marrow total RNA and
normal human bone marrow pA-RNA. Three concentrations of control
RNA, 1, 0.5, and 0.25 mg, and 10 mg of SGD patient RNA were used, as
indicated below the lanes. Blot was probed with [32P]dCTP-labeled
probes, as indicated, and stripped between hybridizations. (B) Immuno-
blotting of cellular proteins extracted from peripheral blood neutrophils iso-
lated as described. Top panel was blotted with rabbit anti–human poly-
clonal C/EBPe antibody. Center panel was blotted with rabbit anti–rat
C/EBP–related protein 1 (Santa Cruz Biotechnology). Bottom panel shows
immunoblotting with mouse anti–human actin antibody. Arrowheads indi-
cate C/EBPe32, C/EBPe27, and C/EBPe14 isoforms.
 
electrophoretically separated, transferred to nitrocellulose, and in-
cubated with primary antibody as described (29). Primary anti-
body was generated in rabbits by Research Genetics, Inc., using a
synthetic peptide encoded in exon 2 of C/EBP
 
e
 
, downstream of
the SGD deletion (DPRAVAVKEEPRGPEGSR). The mem-
branes were washed, incubated with anti–rabbit horseradish per-
oxidase conjugate antibody (ECL Western blot kit; Amersham
Pharmacia Biotech, Inc.), and developed according to the manu-
facturer’s instructions. Membranes were stripped and reblotted
with anti–mouse human 
 
b
 
 actin antibody (Boehringer Mann-
heim) to control for protein loading.
 
In Vitro Mutagenesis Assay.
 
The patient’s mutation was intro-
duced into the pCMV-C/EBP
 
e
 
32
 
 expression vector using a Strata-
gene QuikChange site-directed mutagenesis kit per manufacturer’s
instructions using a complementary oligonucleotide (PAGE purified;
purchased from Genosys Biotech) containing the deletion (5
 
9
 
-CCA
CTA CTT GCC GCC CTC GGC CCT TTG CCT ACC). Pres-
ence of the mutation and maintenance of the vector sequences was
verified by sequencing and restriction enzyme digestion, respectively.
 
Transient Transfections.
 
HeLa cells were maintained in DMEM
(BioWhittaker) supplemented with 10% heat-inactivated FBS
(Life Technologies, Inc.) and penicillin/streptomycin at 37
 
8
 
C and
5% CO
 
2
 
. Cells were plated in 6-well plates and transfected within
24 h, at 30–50% confluency. Transfections, using the Mamma-
lian Transfection System (Stratagene), were performed using 5 
 
m
 
g
reporter plasmid (G-CSF receptor promoter-luc); 1, 2, or 5 
 
m
 
g
inducer plasmid (pCMV-C/EBP
 
a
 
, pCMV-C/EBP
 
e
 
32
 
 isoform,
pCMV-C/EBP
 
e
 
14 isoform, or pCMV-C/EBPe32-SGD, de-
scribed above); and 0.5 mg pCMVb, as described (23, 31). The
DNA content of transfections was normalized, and transfection
was performed according to the manufacturer’s instructions, with
300 ml transfection solution applied to the cells. Samples were
harvested 24 h after transfection.
Luciferase and b-galactosidase activities were measured using a1850 Specific Granule Deficiency Results from C/EBPe Mutation
(Fig. 3). C/EBPe32 has been shown to transactivate the
G-CSF receptor promoter, whereas the C/EBPe14 isoform
lacks transactivating function (23). Transient transfection of
these plasmid constructs showed a significant loss of trans-
activation with the C/EBPe32-SGD isoform (P 5 0.02,
Mann-Whitney U test). The demonstrated in vitro data, as
well as the in vivo SGD phenotype, mark the full length,
32-kD isoform as the major transactivator encoded in the
C/EBPe locus.
The temporal link between granule protein production
and myeloid lineage differentiation is well described: pri-
mary granule proteins are synthesized in myeloblasts and
promyelocytes, secondary granules are produced in myelo-
cytes and metamyelocytes, and tertiary granule proteins are
generated in band and segmented neutrophils (36).
Previous work suggested that C/EBPe functions at the
terminal stages of myeloid differentiation (23, 26). How-
ever, the total absence of patient neutrophil secondary
granules and the selective loss of primary granule defensins
marks an early myelopoietic block at the promyelocyte
transition (Fig. 4). Further evidence for this conclusion comes
from in vitro differentiation experiments using C/EBPe-
deficient stem cells, which do not proceed beyond the pro-
myelocyte stage (26). Other functional defects seen in
mouse and human C/EBPe-deficient neutrophils, such as
loss of tertiary granule gelatinase (27) and abnormalities in
chemotaxis and cytokine expression (6, 27), may occur sec-
ondary to the block at the promyelocyte or later stage.
Functional analysis of the previously developed C/EBPe
knockout mouse model (26, 27) was critical for the inter-
Figure 3. Transcriptional ac-
tivation of normal C/EBPe
and C/EBPe32-SGD. Transient
transfections in HeLa cells were
performed as described. Concen-
trations of labeled inducer plas-
mids (pCMV-C/EBPa, pCMV-
C/EBPe32 isoform, pCMV-C/
EBPe14 isoform, and pCMV-C/
EBPe32-SGD) and reporter plas-
mid, G-CSF receptor promoter-
luc, are given (mg). Sample ac-
tivity was adjusted based on
transfection efficiency, measured
by b-galactosidase activity. Fold
increase in luciferase activity was
calculated from reporter-only
baseline. Data shown represent
the mean (dot) and SE (box) of
four independent experiments.
Significant decreases in luci-
ferase activity were observed be-
tween the pCMV-C/EBPe32
and pCMV-C/EBPe32-SGD iso-
forms (P 5 0.02, Mann-Whit-
ney U test.)
Figure 4. Neutrophil granule
expression during myelopoiesis
and abnormalities in neutrophil-
specific granule deficiency (bro-
ken arrows). The contents of pri-
mary granules, with the exception
of defensins, are present in SGD
neutrophils; however, secondary
and tertiary granules are absent.
G-CSF induces C/EBPe early in
myelopoiesis, which initiates
transcription of granule compo-
nents as indicated.1851 Lekstrom-Himes et al. Brief Definitive Report
pretation of the C/EBPe mutation in SGD. The apparent
multiplicity of C/EBPe target genes at different cell stages
suggests that C/EBPe transactivates a set of early cell stage–
specific genes, inducing normal promyelocyte differentiation
and granule development. Additional evidence supporting
these conclusions comes from recent observations suggesting
that C/EBPe is induced by and transduces the G-CSF signal
in neutrophils early in myelopoiesis (37). Absence of sec-
ondary granules, defensins, eosinophil cationic protein,
eosinophil-derived neurotoxin (12), and platelet a granule
high-molecular-mass von Willebrand factor (14) in SGD
demonstrates a critical role for C/EBPe in the development
of granules and their contents in multiple myeloid lineages.
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